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Abstract
Background: The management of neovascular age-related macular degeneration (nAMD) has
been transformed by the introduction of agents delivered by intravitreal injection which block the
action of vascular endothelial growth factor-A (anti-VEGF agents). One such agent in widespread
use is bevacizumab which was initially developed for use in oncology. Most of the evidence
supporting the use of bevacizumab for nAMD has come from interventional case series and this
clinical trial was initiated because of the increasing and widespread use of this agent in the
treatment of nAMD (an off-label indication) despite a lack of definitive unbiased safety and efficacy
data.
Methods and design: The Avastin® (bevacizumab) for choroidal neovascularisation (ABC) trial is
a double-masked randomised controlled trial comparing intravitreal bevacizumab injections to
standard therapy in the treatment of nAMD. Patients are randomised to intravitreal bevacizumab
or standard therapy available at the time of trial initiation (verteporfin photodynamic therapy,
intravitreal pegaptanib or sham treatment). Ranibizumab treatment was not included in the control
arm as it had not been licensed for use at the start of recruitment for this trial. The primary
outcome is the proportion of patients gaining ≥ 15 letters of visual acuity at 1 year and secondary
outcomes include the proportion of patients with stable vision and mean visual acuity change.
Discussion: The ABC Trial is the first double-masked randomised control trial to investigate the
efficacy and safety of intravitreal bevacizumab in the treatment of nAMD. This trial fully recruited
in November 2007 and results should be available in early 2009. Important design issues for this
clinical trial include (a) defining the control group (b) use of gain in vision as primary efficacy end-
point and (c) use of pro re nata treatment using intravitreal bevacizumab rather than continuous
therapy.
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Background
Age-related macular degeneration (AMD) is the leading
cause of visual loss in patients over the age of 50 years in
Europe and North America [1]. There are 2 forms of the
disease with dry AMD and wet AMD (neovascular or exu-
dative AMD). Neovascular age-related macular degenera-
tion (nAMD) is characterised by choroidal
neovascularisation (CNV) and is responsible for 75% of
visual loss due to AMD despite only accounting for 25%
of all cases [2].
Historically the prognosis for patients with subfoveal
nAMD has been poor with the established treatment of
verteporfin photodynamic therapy (PDT) only showing
modest efficacy in reducing visual loss in patients with
well-defined (predominantly classic or classic no occult)
sub-types of nAMD [3]. Until the introduction of new
therapies, there was no effective treatment for poorly
defined (minimally classic or occult) subtypes of nAMD.
One of the key mediators implicated in the pathogenesis
of CNV in nAMD is vascular endothelial growth factor-A
(VEGF). New treatments have targeted VEGF with the
introduction of agents administered by injection into the
vitreous cavity with high binding specificity to VEGF
(anti-VEGF agents). There are three agents which block
the action of VEGF-A currently in clinical use. These agents
are administered by intraocular (intravitreal) injections
with repeated injection necessary every 4–6 weeks
depending on the agent.
The first drug developed and licensed for use was
pegaptanib sodium (Macugen®, Pfizer Inc, New York,
NY). This agent is an oligonucleotide with high binding
specificity for the 165 isoform of VEGF. The pivotal phase
III randomised controlled trial reported a benefit in stabil-
ising vision over sham treatment (70% of patients lost less
than 15 letters of visual acuity at 1 year in treated groups
compared to 55% in sham treated group) but disappoint-
ingly only 6% of treated patients improved vision by 15
letters or more at one-year follow-up [4].
Another agent which has gained favour with ophthalmol-
ogists is bevacizumab (Avastin®, Genentech Inc., South
San Francisco, CA). This full-length monoclonal antibody
binds to and blocks the action of all isoforms of VEGF. It
was initially developed as an intravenous agent in the
treatment of metastatic colorectal cancer [5] before oph-
thalmologists reported promising results using bevacizu-
mab as an intravitreous treatment for nAMD in case series
[6,7]. It has gained popularity worldwide as a treatment
option for nAMD due to the low drug cost of treatment
when used as an intraocular agent. Despite the wide-
spread off-label ocular use of bevacizumab, there have
been no definitive prospective, double-masked, ran-
domised, controlled trials investigating the safety and effi-
cacy of intravitreal bevacizumab for the treatment of
nAMD.
Ranibizumab (Lucentis®, Genentech Inc., San Francisco,
CA) is an antibody fragment developed from the bevaci-
zumab molecule with increased binding affinity for all
isoforms of VEGF. It has been shown to be more effica-
cious than sham treatment (placebo) in treating mini-
mally classic or occult CNV [8] and PDT [9] in treating
predominantly classic CNV. Patients treated with
monthly intravitreal injections of ranibizumab for 1–2
years showed better visual acuity outcomes than patients
treated with sham or PDT (40–33% of ranibizumab
treated patients improving visual acuity by 15 letters or
more compared to 4% of sham treated and 6% of PDT
treated patients). Ranibizumab was licensed for use in the
treatment of nAMD after the start of recruitment for this
study and so was not included as a comparator arm. Ran-
domised controlled trials comparing bevacizumab to
ranibizumab have commenced recruitment but are likely
to take a further 2–3 years before they report outcome
data. In addition it is important to consider that a 4
weekly dosing interval for both bevacizumab and ranibi-
zumab is planned to be used in these trials, which, given
that studies have suggested a 6 weekly dosing schedule
may be adequate for intravitreal bevacizumab [10], elim-
inates one of the main potential advantages bevacizumab
over ranibizumab – the need for less intravitreal injections
and less intensive patient follow-up.
In 2005, the use of bevacizumab in the treatment of
nAMD was increasing both in the USA and Europe as oph-
thalmologists had received early promising reports of effi-
cacy from interventional case series with approximately 1/
3 of patients improving vision. At that time, the only
licensed agents in the treatment of subfoveal nAMD were
PDT and intravitreal pegaptanib injections which though
associated with reducing visual loss, had shown only
modest efficacy in improving vision (only approximately
5–6% of patients improving vision with either of these
agents in randomised controlled trials). In addition to
perceived better efficacy, repackaging pharmacies provide
intravitreal bevacizumab for a fraction of the cost of
pegaptanib, verteporfin or ranibizumab. However there
are no large scale prospective, double-masked, ran-
domised controlled trials supporting the use of bevacizu-
mab for nAMD and there was therefore a need to design a
clinical trial to investigate the efficacy and safety of intra-
vitreal bevacizumab injections to standard therapy (PDT
or pegaptanib) in the treatment of nAMD.
The current trial is designed to investigate whether intrav-
itreal bevacizumab injections are an effective and safe
treatment for nAMD when compared to standard therapy.
It will also provide exploratory data on the efficacy of bev-Trials 2008, 9:56 http://www.trialsjournal.com/content/9/1/56
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acizumab when compared to either PDT, pegaptanib or
sham treatment alone.
Methods and design
Double-masked, randomised, controlled trial with 2 par-
allel treatment groups. Eligible patients were randomised
in a 1:1 ratio to receive either intravitreal bevacizumab or
standard therapy (either PDT, pegaptanib intravitreal
injections or sham intravitreal injections). Only one eye
per patient was included in the study and this was selected
prior to randomisation. Standard therapy was determined
prior to trial enrolment at which point patients were allo-
cated to treatment groups by minimisation – a dynamic
process which reduces the imbalance between trial arms
with respect to standard treatment eligibility and site.
During trial recruitment, patients with well-defined (clas-
sic, no occult or predominantly classic CNV) were funded
for PDT in line with National Institute for Health and
Clinical Excellence (NICE) guidance. However there was
no national funding in place for patients with poorly
defined forms of nAMD (minimally classic or occult
CNV) as PDT had not shown efficacy over natural history
for these lesion subtypes and the new anti-VEGF agents
(pegaptanib and ranibizumab) had not been subject to
appraisal by NICE. National Health Service (NHS) treat-
ment was delivered on a case by case basis with many
patients not funded for NHS treatment. Eligible patients
with minimally classic or occult no classic CNV were
either randomised to pegaptanib or sham treatment
(based on funding of pegaptanib therapy). A summary of
the enrolment and randomisation process in shown in
Figure 1.
During the later stages of trial recruitment, after ranibizu-
mab had been introduced into clinical practice, if patients
were funded for ranibizumab, they were excluded from
enrolment to this clinical trial. At the time of recruitment
for this trial, since many patients who were refused public
funding of treatment did not have medical insurance and
could not afford the costs of private treatment, a signifi-
cant proportion of patients remained untreated and there-
fore would consider involvement in a trial in which they
were randomised to active treatment (intravitreal bevaci-
zumab) or to a sham arm. Previous precedents for such
active treatment versus sham or no treatment trial
included the pegaptanib VISION trial [4] or the Lucentis
MARINA trial [8]. The ABC trial fully recruited its patient
population before final NICE guidance was issued on the
use of pegaptanib or ranibizumab for treating nAMD in
the NHS.
Objectives
Primary
To test the hypothesis that in patients being treated for
choroidal neovascularisation (CNV) due to age-related
macular degeneration (nAMD), intravitreal bevacizumab
injections can improve visual acuity (defined as a gain of
≥ 15 letters) in the treated eye in a greater proportion of
patients than standard therapy after 12 months
Secondary
To test the hypothesis that in patients being treated for
CNV due to age-related macular degeneration (nAMD):
1. Intravitreal bevacizumab injections are not associated
with increased ocular and systemic adverse events com-
pared to standard therapy after 12 months
2. Intravitreal bevacizumab injections can stabilise visual
acuity (defined as a loss of <15 letters of visual acuity) in
a greater proportion of patients than standard therapy
after 12 months
3. Intravitreal bevacizumab injections can improve visual
acuity (defined as a gain of ≥ 10 letters) in a greater pro-
portion of patients than standard therapy after 12 months
4. Intravitreal bevacizumab injections can improve visual
acuity in a greater proportion of patients than standard
therapy at the 6 month time-point
5. Intravitreal bevacizumab injections can improve mean
visual acuity when compared to standard therapy at the 12
month time-point
6. Intravitreal bevacizumab injections can lead to a greater
reduction in macular thickness than in patients receiving
standard therapy at the 6 and 12 month time-points
7. Intravitreal bevacizumab injections can lead to a greater
reduction in leakage from CNV than in patients receiving
standard therapy at the 12 month time-point
Eligibility
Inclusion criteria
￿ Age >50 years
￿ Primary subfoveal CNV lesions secondary to AMD in the
study eye
￿ An occult CNV must have presumed evidence of disease
progression, defined as one or more of the following:
1. Deterioration of best corrected vision by 1 Snellen line
or 5 letters on Early Treatment of Diabetic Retinopathy
Study (ETDRS) charts within the past 3 months due to
progression of CNV
2. Presence of sub or intraretinal bloodTrials 2008, 9:56 http://www.trialsjournal.com/content/9/1/56
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Summary of trial design Figure 1
Summary of trial design.Trials 2008, 9:56 http://www.trialsjournal.com/content/9/1/56
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3. Growth of lesion size on fluorescein angiography by
more than 10% in the past 3 months
￿ Evidence of central macular thickening assessed using
optical coherence tomography (OCT)
￿ Total lesion size < 12 optic disc areas including all con-
tiguous lesion components.
￿ Area of fibrosis < 25% of the total lesion area
￿ Area of subretinal blood less than 50% of total lesion
area
￿ Best corrected visual acuity, using ETDRS charts of 6/12
to 6/96 (Snellen equivalent) in the study eye
Only one eye is assessed in the study. If both eyes are eli-
gible, the one with the better visual acuity will be selected
for treatment and study unless, based on medical reasons,
the investigator deems the other eye the more appropriate
candidate for treatment and study.
Exclusion criteria
Prior treatment with external-beam radiation therapy,
transpupillary thermotherapy (TTT), thermal laser, or
PDT in the study eye
Treatment with verteporfin in the non-study eye less than
7 days preceding Day 0,
￿ Previous participation in a clinical trial (for either eye)
involving anti-angiogenic drugs (pegaptanib, bevacizu-
mab, anecortave acetate, protein kinase C inhibitors, etc.)
￿ Previous intravitreal drug delivery (e.g., intravitreal cor-
ticosteroid injection or device implantation) in the study
eye
￿ History of vitrectomy surgery in the study eye
￿ History of greater than mild non-proliferative diabetic
retinopathy or any diabetic maculopathy
￿ History of retinal vascular occlusions (if considered
likely to compromise potential for visual acuity improve-
ment)
￿ History of glaucoma filtering surgery in the study eye
￿ History of corneal transplant in the study eye
￿ History of submacular surgery or other surgical interven-
tion for AMD in the study eye
￿ Previous participation in any studies of investigational
drugs within 1 month preceding Day 0 (excluding vita-
mins and minerals)
￿ Current or intending use of warfarin or known abnor-
mal blood clotting
Lesion characteristics
￿ Subretinal haemorrhage in the study eye that involves
the centre of the fovea, if the size of the haemorrhage is
either >50% of the total lesion area or >1 disc area in size
￿ Subfoveal fibrosis or atrophy in the study eye.
￿ CNV in either eye due to causes other than AMD, such
as ocular histoplasmosis, trauma, or pathologic myopia
￿ Retinal pigment epithelial tear involving the fovea in the
study eye
Concurrent ocular conditions
￿ Any concurrent intraocular condition in the study eye
(e.g., cataract or diabetic retinopathy) that, in the opinion
of the investigator, could either require medical or surgi-
cal intervention during the 12 month study period to pre-
vent or treat visual loss that might result from that
condition, or if allowed to progress untreated, could likely
contribute to loss of at least 2 Snellen equivalent lines of
best corrected visual acuity over the 12 month study
period
￿ Active intraocular inflammation (grade trace or above)
in the study eye
￿ Current vitreous haemorrhage in the study eye
￿ History of rhegmatogenous retinal detachment or mac-
ular hole in the study eye
￿ History of idiopathic or autoimmune-associated uveitis
in either eye
￿ Infectious conjunctivitis, keratitis, scleritis, or endoph-
thalmitis in either eye
￿ Aphakia or absence of the posterior capsule in the study
eye. Previous violation of the posterior capsule in the
study eye is also excluded unless it occurred as a result of
YAG posterior capsulotomy in association with prior, pos-
terior chamber intraocular lens implantation.
￿ Spherical equivalent of the refractive error in the study
eye demonstrating more than -8 diopters of myopia or
signs of pathologic myopia with a refraction of 4–8 diopt-
ersTrials 2008, 9:56 http://www.trialsjournal.com/content/9/1/56
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For subjects who have undergone prior refractive or cata-
ract surgery in the study eye, the preoperative refractive
error in the study eye cannot exceed -8 diopters of myopia.
￿ Intraocular surgery (including cataract surgery) in the
study eye within 2 months preceding Day 0
￿ Uncontrolled glaucoma in the study eye (defined as
intraocular pressure >30 mmHg despite treatment with
anti-glaucoma medication)
Concurrent systemic conditions
￿ Premenopausal women not using adequate contracep-
tion
￿ History of other disease, metabolic dysfunction, or clin-
ical laboratory finding giving reasonable suspicion of a
disease or condition that contraindicates the use of an
investigational drug or that might affect interpretation of
the results of the study or render the patient at high risk
for treatment complications
￿ Current treatment for active systemic infection
￿ Recent stroke, or cardiac event in the last 6 months,
uncontrolled angina or hypertension.
Other
￿ History of allergy to fluorescein
￿ Inability to obtain fundus photographs or fluorescein
angiograms of sufficient quality to be analyzed and
graded by the central reading centre
￿ Inability to comply with study or follow-up procedures
All patients referred to the Trial Centres with active CNV
due to AMD were informed of the clinical trial and were
given patient information sheets. Those patients who
were keen to participate were screened with those meeting
the eligibility criteria invited to enrol. The study is con-
ducted according to ICHGCP (International Conference
on Harmonisation for Good Clinical Practice in clinical
research), as set out in the European Union Clinical Trials
Directive (2001) and associated UK Regulations (2004),
which adhere to the principles of the Helsinki Declara-
tion.
Interventions
Figure 2 summarises the trial treatments.
Active intervention. Intravitreal bevacizumab injections
Bevacizumab was administered by six weekly intravitreal
injections (dose of 1.25 mg in 0.05 ml per injection) and
a treatment strategy of 3 treatments with further injections
as needed based on investigator driven retreatment with
standardised retreatment criteria was used reflecting the
real world use of this agent at the time of the trial (3 to 9
injections in total in 54 weeks). The bevacizumab injec-
tions were prepared by Moorfields Pharmaceuticals in line
with UK pharmaceutical regulatory standards.
Control intervention. Intravitreal pegaptanib injections
These were given as per the product license with a dose of
0.3 mg of pegaptanib in 0.09 ml given as continuous ther-
apy by intravitreal injection every 6 weeks for 1 year (9
injections in 54 weeks). This reflects the dosing and fre-
quency of treatment used in the pivotal VISION ran-
domised controlled trial reporting the efficacy and safety
of pegaptanib in the treatment of nAMD [4].
Control intervention. Verteporfin photodynamic therapy
Verteporfin PDT is performed as described elsewhere [11].
Briefly, an unmasked trial member not involved in any
outcome assessments and trained in the importance of
maintaining masking prepares an infusion of verteporfin
(6 mg/m2 of body surface area) in 30 ml of 5% dextrose
after calculating body surface area from a nomogram
based on the height and weight of the patient. Intravenous
infusion of the solution is given over 10 minutes after cov-
ering the infusion line and pump to maintain masking
(the solution is green). Fifteen minutes after the start of
the infusion, the unmasked ophthalmologist applies laser
light (diode laser 689 nm) for 83 seconds (light exposure
of 50 J/cm2, intensity 600 mW/cm2) to the CNV lesion
through a fundus contact lens of known magnification.
The laser spot size for each treatment is determined by
measuring the greatest linear diameter of the CNV lesion
on fluorescein angiography and adding an addition 1000
μm in order to provide an additional margin of 500 μm
around the lesion. After the treatment the patient is
advised to avoid bright sunlight for 48 hours to prevent
possible photosensitive reactions.
Placebo treatment. Sham intravitreal injections
In line with previous randomised controlled trials [4,8],
sham intravitreal injections rather than placebo intravit-
real injections of vehicle are used. Sham injections are per-
formed by following the procedure used to prepare the
eye for injection but instead of an intravitreal injection,
the hub of an empty 1 ml syringe is applied firmly to the
conjunctiva to mimic an active injection. This procedure
is ethically acceptable as it does not subject the patient to
the potential risk of sight-threatening infection associated
with intravitreal injections whilst maintaining masking by
closely resembling an active injection procedure.
Measures to maintain masking
Placebo PDT
This is used for patients randomised to bevacizumab in
cases in which standard care is PDT. The procedure is
identical to that used for active verteporfin PDT except 5%Trials 2008, 9:56 http://www.trialsjournal.com/content/9/1/56
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dextrose is used as placebo with no verteporfin added.
This is in line with previous studies [11]. Care was taken
to ensure that the intravenous infusion pump and line
were covered as the active verteporfin solution is green
while the placebo infusion is a clear solution.
Additional use of sham injections
As the treatment of patients randomized to bevacizumab
or pegaptanib involves the comparison of a pro re nata
treatment (bevacizumab) to a treatment given continu-
ously (nine, six weekly intravitreal injections of
pegaptanib), to maintain masking, sham treatments were
given to patients randomised to bevacizumab not requir-
ing intravitreal treatment at that visit (weeks 18 to 48)
based on the standardised retreatment criteria. This was to
maintain masking as pegaptanib was delivered as contin-
uous therapy (as per the product license) whereas bevaci-
zumab was given as 3 initial injections with further
retreatment as necessary using standardised retreatment
criteria.
Evaluating the success of masking
Adequacy of masking was assessed by means of a ques-
tionnaire to patients and the masked investigator when
the patient left the study to determine views on treatment
allocation
Outcome measures
Primary
1. Visual acuity score
An improvement in visual acuity is defined as a gain of 15
letters or more (3 lines) of best corrected visual acuity
score at the 12 month time point compared with baseline,
using ETDRS visual acuity charts and visual acuity meas-
urement at a starting distance of 4 metres.
Secondary
1. Other visual acuity based outcomes
In addition to the conventional end-point of 15 or more
letter gain in visual acuity, more recently a clinical trial vis-
Summary of trial treatments Figure 2
Summary of trial treatments.Trials 2008, 9:56 http://www.trialsjournal.com/content/9/1/56
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ual acuity end-point of 10 or more letters has been sug-
gested [12] and so the proportion of patients improving
visual acuity using this end-point in both the bevacizu-
mab treated and standard therapy treated group will also
be described and analysed as a secondary outcome meas-
ure for the 6 month and 12 month time-points. Other
alternative end-points of the proportion of patients gain-
ing 5 or more letters and patient losing less than 15 letters
of best corrected visual acuity score will also be examined
similarly as secondary end-points. The mean change in
visual acuity in the two groups at 12 months will also be
reported.
2. Optical Coherence Tomography based retinal thickness
measurement
Stratus OCT (Carl Zeiss Meditec, Inc) was used to obtain
retinal thickness measurements using fast macular thick-
ness mapping scan protocol. Radial line scanning (or
cross-hairs when radial line scans not possible) was used
to determine the presence or absence of macular fluid
(intra-retinal cysts and sub-retinal fluid) at each visit. The
mean change in macular thickness in the bevacizumab
and standard therapy groups at the 6 and 12 month time-
points will be reported.
3. Contrast sensitivity measurement
Pelli-Robson charts were used to measure contrast sensi-
tivity [13].
4. Reading ability measurement
Minnesota Reading (MNREAD) charts [14] were used to
assess reading ability with measurement of maximum
reading speed, critical print size and reading acuity.
Adverse events
These will be documented and serious adverse events will
be reported to the Medicines and Healthcare Products reg-
ulatory Agency (MHRA). Both ocular and systemic
adverse events will be noted. There will also be a specific
report of any adverse events meeting the Antiplatelet Tri-
alists' Collaboration (APTC) criteria [15]. As this is a dou-
ble-masked trial, adverse events will be reviewed by the
Data Monitoring Committee (DMC) who may ask to be
unmasked to treatment allocation.
Visit schedule and assessments
Randomisation and treatment occur up to 14 days after a
screening visit (or on the same day). After baseline treat-
ment, patients attended again at week 1 for a safety visit
(no treatment given). Further follow-up visits with repeat
treatment occurred at week 6, 12, 18, 24, 30, 36, 42 and
week 48. The study exit visit occurs at week 54 (1 year).
This gives 9 treatment visits with the first 3 intravitreal
bevacizumab treatments compulsory (baseline, week 6
and week 12) with further treatments as needed based on
standardised retreatment criteria (at weeks 18, 24, 30, 36,
42, 48). Safety assessments consist of recording all adverse
events, monitoring of blood pressure and pulse at every
visit with blood tests at baseline, week 24 and study exit
(week 54).
Study assessments include functional outcome measures
including best-corrected visual acuity assessments, con-
trast sensitivity measurement and measurement of read-
ing ability (using MNREAD acuity charts). Structural
outcome was assessed at every visit using OCT measures
of retinal thickness and qualitative features of CNV activ-
ity. Fundus fluorescein angiography was performed at
baseline and weeks 6, 12, 24, 36 48 and week 54 visits
(with additional fluorescein angiography at week 1 for the
first 20% of patients) to allow assessment of any change
in CNV size and leak. The trial visits are summarised in
Figure 3.
Trial size
A Fisher's exact test with a 0.050 two-sided significance
level will have 90% power to detect the difference
between a Group 1 proportion, π1, of 0.300 and a Group
2 proportion, π2, of 0.060 when the sample size in each
group is 57. To allow for a potential 12% loss to follow-
up we plan to recruit 65 patients per treatment group.
(Previous clinical trials for nAMD [4,11], suggest that
upto 10% of patients may be lost to follow-up during the
trial). With these numbers we would have 82% power to
detect differences of 0.25 and 0.06.
Statistical analyses
Baseline characteristics of patients in each treatment arm
will be summarised. The proportion of patients who gain
15 letters of best corrected visual acuity (BCVA) or more
in each group at 12 months will be provided with 95%
confidence intervals computed by the exact binomial
method. A Fisher's exact test will be conducted to assess
whether or not any observed difference in these propor-
tions is statistically significant. Odds ratios will be
reported together with 95% confidence intervals to illus-
trate the contrast between bevacizumab and standard
treatment. If any imbalance in prognostic factors is
detected, logistic regression will be conducted to assess
the impact of any imbalance and adjusted odds ratios
reported. Data will be analysed according to the group to
which patients were originally assigned (i.e. intent to
treat). In addition to the intention to treat analysis, a per
protocol analysis will be carried out.Trials 2008, 9:56 http://www.trialsjournal.com/content/9/1/56
Page 9 of 12
(page number not for citation purposes)
The proportion of patients in each group who at 6 and 12
months have
a) gained 5 letters of BCVA
b) gained 10 or more letters of BCVA
c) lost fewer than 15 letters of BCVA
will be reported with 95% confidence intervals together
with a description of the average change in OCT deter-
mined central macular thickness and BCVA at 12 months.
Comparative results (odds ratios and mean differences)
will also be reported with 95% confidence intervals. These
form part of the secondary end-points for the trial.
Kaplan Meier plots will be constructed to examine rates of
improvement of BCVA and Cox regression or log rank
tests conducted. Adherence to the proportional hazards
assumption will be assessed.
Adverse events will be tabulated by treatment group.
Trial organisation
The trial centres and investigators are listed in Table 1
Trial Steering Committee
The Trial Steering Committee monitor and supervise the
trial and comment on any proposed major protocol
amendments (Table 1).
Data Monitoring Committee
The data monitoring committee (DMC) includes 2 inde-
pendent ophthalmologists with a specialist interest in ret-
inal disease and an independent statistician with clinical
trials experience (Table 1). No formal interim analysis is
planned. The trial statistician will report to an independ-
ent DMC which will monitor the trial in all its respects. It
will review safety data on a monthly basis and if appropri-
ate will conduct an unmask safety analysis.
Summary of trial visits Figure 3
Summary of trial visits.Trials 2008, 9:56 http://www.trialsjournal.com/content/9/1/56
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Trial Operations Committee
An operations committee consisting of the Chief Investi-
gator, the Principal Investigator at the co-ordinating cen-
tre and the Trial Manager meet every week. During these
meetings, the committee reviews the progress of the study
identifying any problems or issues at all 3 sites.
Trial co-ordination
The trial is centrally co-ordinated from the Clinical Trials
Unit (CTU) at Moorfields Eye Hospital. This provides the
telephone randomisation service (which uses minimisa-
tion) and is responsible for data management.
Trial documentation and data collection
All trial centres are supplied with a Protocol, Standard
Operating Procedures guidance, Source Documentation
and Case Report Forms. Serious adverse events are
reported to Moorfields Eye Hospital (the Trial Sponsor)
and to the MHRA.
Ethics and competent authority review
Applications to UK Main and Local Research Ethics Com-
mittees (REC) have received favourable opinions and a
Clinical Trials Authorisation has been issued by the
MHRA.
Publication policy
The results of this trial will be submitted for publication
to peer-review medical journals regardless of whether the
outcome is in favour of the trial intervention.
Trial timetable
Trial start
August 2006
Trial recruitment completed
November 2007
Trial end
December 2008
Trial duration
2 years, 5 months
Duration of each patient's participation
1 year (54 weeks)
Discussion
Since the first reports of the efficacy of bevacizumab in
treating nAMD, there has been increasing use of this drug
for this unlicensed indication and bevacizumab is proba-
bly the most widely used drug worldwide to treat nAMD
because of its low unit cost despite the availability of alter-
native licensed therapies. However, most of the evidence
supporting its use comes from interventional case and in
this age of evidence-based medicine, there is no data from
prospective, double-masked, multi-centre randomised
controlled trials comparing the efficacy and safety of intra-
vitreal bevacizumab to other therapies in the treatment of
nAMD. The Avastin® (bevacizumab) for CNV trial will be
the first definitive, prospective, double-masked, multi-
Table 1: Trial management
Trial Operations Committee
Adnan Tufail Chief Investigator, Moorfields Eye Hospital, London, UK
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Data Monitoring Committee
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Marion Campbell Professor of Health Services Research, University of Aberdeen, UK
Robyn Guymer Professor of Ophthalmology, University of Melbourne, Australia
Frank G. Holz Professor of Ophthalmology, University of Bonn, GermanyTrials 2008, 9:56 http://www.trialsjournal.com/content/9/1/56
Page 11 of 12
(page number not for citation purposes)
centre, randomised controlled trial reporting unbiased
efficacy and safety data for intravitreal bevacizumab in the
treatment of nAMD with results expected in early 2009.
In addition, the trial will provide information about the
effect of treatment on structural (qualitative and quantita-
tive OCT measures) and other functional outcome meas-
ures (including contrast sensitivity and reading ability).
Exploratory analyses including possible prognostic indi-
cators will also be of interest.
The Avastin® (bevacizumab) for CNV trial incorporates
several novel features in the trial design. In contrast to pre-
vious multi-centre randomised controlled trials in the
field [3,4,8,9], this study is the first to use visual gain as
the primary outcome measure rather than stabilisation in
vision with secondary outcomes including mean visual
acuity change to maximise use of data points. This shift
from stabilisation to visual gain as the primary end-point
reflects the changing expectation of both patients and
physicians in the treatment of nAMD.
Treatment in the comparator or control arm is determined
by funding of standard therapy. This may be viewed as
both a strength and a weakness of the study. Though not
allowing comparison with a single agent, the choice of a
comparator arm with one of 3 different treatments (2
active and one sham) reflects the usual treatment of
patients in the NHS at the time of recruitment. It does not
undermine the analysis of results as all treatments in the
comparator arm have shown to offer patients a similar
chance of improvement in vision (a maximum propor-
tion of 0.06 improving vision with either comparator
treatment at one year [3,4]). Ranibizumab was not one of
the therapies included in the comparator arm as this drug
only reached market after the start of recruitment and was
not widely available during the recruitment phase of this
trial.
Another novel design feature is the use of pro re nata treat-
ment with bevacizumab (based on investigator deter-
mined retreatment with standardised retreatment criteria)
after three initial treatments. This approach reflects clini-
cal practice with clinicians using retreatment criteria to
determine further treatment with anti-VEGF agents and
should make the results more translatable into clinical
practice. However this is distinct from the approach taken
in the pivotal anti-VEGF agent trials in which a continu-
ous treatment strategy was used. The use of continuous
pegaptanib (reflecting the product license for pegaptanib)
in the comparator arm is identical to the dosing used in
the phase III trial comparing pegaptanib to sham treat-
ment [4].
The ABC trial is the first multi-centre randomised control-
led trial to use OCT in all patients both using retinal thick-
ness data to assess outcome and to use qualitative
interpretation of scans in deciding on retreatment of
patients with AMD. Previous randomised trials have used
OCT only in a sub-set of patients with no use of OCT
based retreatment criteria.
In summary, the ABC trial uses a pragmatic yet high-qual-
ity trial design to evaluate the efficacy of intravitreal beva-
cizumab in the treatment of nAMD. The treatment
strategy used reflects the clinical use of bevacizumab in
treating nAMD and should help clinicians in translating
the results from the trial into clinical practice. The trial
aims to augment the evidence base for therapeutic options
in the treatment of nAMD.
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